Abstract
Purpose The use of mobile health (mHealth) technologies to augment patient care, enables providers to communicate remotely with patients enhancing the quality of care and patient engagement. Few studies addressed barriers to its implementation, especially in medically underserved populations.
Methods A cross-sectional study of 151 cancer patients was conducted at an academic medical center in the United States. A trained interviewer performed structured interviews regarding the barriers and facilitators of patients’ current and desired utilization of technology for healthcare services.
Results Of the 151 participants, 35.8% were male and ages ranged from 21-104 years. Only 73.5% of participants currently have daily access to internet, and 68.2% currently own a smartphone capable of displaying mobile applications. Among all participants, utilization of a daily mHealth application was significantly higher in patients with a college-level degree (OR; 2.78, p<0.01) and lower in older patients (OR; 0.05, p<0.01). Differences in utilization when adjusted for current smartphone use and daily access to internet were nonsignificant. Among smartphone users, the desire to increase cancer knowledge was associated with a higher likelihood of utilizing a mHealth application (OR; 261.53, p<0.01).
Conclusion The study suggests the access to mobile technology is the predominant determinant of utilization. Healthcare organizations should consider these factors when launching patient engagement platforms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project received no external funding from any public or private sources.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author Email Addresses: Rashmika Potdar (rpotdar{at}geisinger.edu)
Arun Thomas (thomasa{at}einstein.edu)
Matthew DiMeglio (matthewdi{at}pcom.edu)
Kamran Mohiuddin (mohiuddink{at}einstein.edu)
Djeneba Audrey Djibo (adjibo{at}icloud.com)
Krzysztof Laudanski (klaudanski{at}gmail.com)
Claudia Dourado (DouradoC{at}einstein.edu)
John Leighton (LEIGHTOJ{at}einstein.edu)
Jean Ford (fordjean{at}einstein.edu)
Data Availability
Data will be made accessible upon reasonable request and in accordance with institutional review board data transfer guidelines.
